Xeris Biopharma
(NASDAQ) XERS
Xeris Biopharma Financials at a Glance
Market Cap
$1.24B
Revenue (TTM)
$314.85M
Net Income (TTM)
$12.01M
EPS (TTM)
$0.07
P/E Ratio
109.92
Dividend
$0.00
Beta (Volatility)
1.27 (Average)
Dividend
$0.00
Beta (Volatility)
1.27 (Average)
Price
$7.36
Volume
54,973
Open
$7.28
Price
$7.36
Volume
54,973
Open
$7.28
Previous Close
$7.36
Daily Range
$7.28 - $7.51
52-Week Range
$4.52 - $10.08
Estimated Earnings Date
Aug 6, 2026
Dividend
$0.00
Beta (Volatility)
1.27 (Average)
Price
$7.36
Volume
54,973
Open
$7.28
Previous Close
$7.36
Daily Range
$7.28 - $7.51
52-Week Range
$4.52 - $10.08
Estimated Earnings Date
Aug 6, 2026
XERS News
XERS: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Xeris Biopharma
Industry
Pharmaceuticals
Sector
Health CareEmployees
435
CEO
John Patrick Shannon, Jr.
Website
www.xerispharma.comHeadquarters
Chicago, IL 60601, US
XERS Financials
Key Financial Metrics (TTM)
Gross Margin
81.59%
Operating Margin
11.40%
Net Income Margin
3.81%
Return on Equity
735.00%
Return on Capital
48.39%
Return on Assets
3.06%
Earnings Yield
0.91%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$1.24B
Shares Outstanding
172.64M
Volume
54.97K
Avg. Volume
1.67M
Financials (TTM)
Gross Profit
$256.89M
Operating Income
$35.90M
EBITDA
$46.13M
Operating Cash Flow
$48.53M
Capital Expenditure
-$1.30M
Free Cash Flow
$47.23M
Cash & ST Invst.
$111.75M
Total Debt
$37.33M
Xeris Biopharma Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$83.13M
+38.3%
Gross Profit
$69.84M
+35.9%
Gross Margin
84.02%
N/A
Market Cap
$1.24B
N/A
Market Cap/Employee
$3.15M
N/A
Employees
394
N/A
Net Income
$2.23M
+124.2%
EBITDA
$12.33M
+903.9%
Quarterly Fundamentals
Total Cash
$111.75M
+91.2%
Total Debt
$37.33M
-86.1%
Accounts Receivable
$56.30M
+21.5%
Inventory
$74.23M
+40.9%
Long Term Debt
$31.06M
-87.6%
Short Term Debt
$6.27M
-65.3%
Return on Assets
3.06%
N/A
Return on Invested Capital
13.13%
N/A
Free Cash Flow
$9.55M
+195.0%
Operating Cash Flow
$9.87M
+198.4%